PETQ vs. OCS, ABUS, OFIX, CCCC, TSHA, KALV, APLT, AUNA, NVRO, and HUMA
Should you be buying PetIQ stock or one of its competitors? The main competitors of PetIQ include Oculis (OCS), Arbutus Biopharma (ABUS), Orthofix Medical (OFIX), C4 Therapeutics (CCCC), Taysha Gene Therapies (TSHA), KalVista Pharmaceuticals (KALV), Applied Therapeutics (APLT), Auna (AUNA), Nevro (NVRO), and Humacyte (HUMA). These companies are all part of the "medical" sector.
PetIQ (NASDAQ:PETQ) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.
PetIQ currently has a consensus price target of $29.00, indicating a potential upside of 77.70%. Oculis has a consensus price target of $29.14, indicating a potential upside of 143.87%. Given Oculis' higher possible upside, analysts clearly believe Oculis is more favorable than PetIQ.
PetIQ received 291 more outperform votes than Oculis when rated by MarketBeat users. However, 85.00% of users gave Oculis an outperform vote while only 65.53% of users gave PetIQ an outperform vote.
95.0% of PetIQ shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 9.3% of PetIQ shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
PetIQ has higher revenue and earnings than Oculis.
In the previous week, Oculis had 7 more articles in the media than PetIQ. MarketBeat recorded 8 mentions for Oculis and 1 mentions for PetIQ. PetIQ's average media sentiment score of 0.50 beat Oculis' score of 0.03 indicating that PetIQ is being referred to more favorably in the media.
PetIQ has a net margin of 0.19% compared to Oculis' net margin of 0.00%. PetIQ's return on equity of 11.72% beat Oculis' return on equity.
Summary
PetIQ beats Oculis on 9 of the 14 factors compared between the two stocks.
Get PetIQ News Delivered to You Automatically
Sign up to receive the latest news and ratings for PETQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PETQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
